TriSalus Life Sciences In...
4.69
-0.37 (-7.31%)
At close: Jan 14, 2025, 2:53 PM
4.69
0.00%
After-hours Jan 14, 2025, 02:54 PM EST
undefined%
Bid 4.14
Market Cap 143.01M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.92
PE Ratio (ttm) -2.44
Forward PE n/a
Analyst Buy
Ask 5.98
Volume 10,435
Avg. Volume (20D) 37,708
Open 4.83
Previous Close 5.06
Day's Range 4.62 - 4.91
52-Week Range 3.50 - 10.42
Beta undefined

About TLSI

TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular...

Sector Healthcare
IPO Date Feb 8, 2021
Employees 107
Stock Exchange NASDAQ
Ticker Symbol TLSI

Analyst Forecast

According to 6 analyst ratings, the average rating for TLSI stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 134.54% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

TriSalus Life Sciences Inc. is scheduled to release its earnings on Mar 31, 2025, before market opens.
Analysts project revenue of $8.22M, reflecting a 43.68% YoY growth and earnings per share of -0.31, making a -80.13% decrease YoY.
2 months ago · Source
-10.89%
TriSalus Life Sciences shares are trading lower af... Unlock content with Pro Subscription